Immvira Group Company, a Shenzen, China-based biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics, closed a $58m Series B financing.
The round was led by Huagai Capital, with participation from Apricot Capital, Cowin Capital.
The company intends to use the funds for the preclinical and clinical development of existing product pipelines, the discovery of new candidate in its early stage, and the potential strategic collaboration with domestic and global partners.
Led by Dr. Grace Zhou，Chairman of BOD and CEO, Immvira is a biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, which not only improves the replicating ability of the virus, but also further improves the oncolytic activity of the virus and promotes the immune response. Its oncolytic virus product T3 has launched clinical studies in Australia, China and the United States simultaneously to explore the treatment of multiple solid tumors. In addition to mono and combination therapies by T3011 (intratumoral injection), Immvira has additional 4 products planned in its pipeline covering multiple indications, including lung cancer and liver cancer (T3011-systemic administration), malignant brain tumors (C5252), virus-resistant solid tumors and hematological malignancies.